- Acumen Powered by Robins Kaplan LLP®
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
June 17, 2024Emily Tremblay Named IP Rising Star by Euromoney in 2024 Women in Business Law Awards
-
June 17, 2024Three Robins Kaplan Partners Named BTI Client Service All-Stars
-
June 13, 2024Brendan Johnson Named South Dakota Trial Lawyer of The Year
-
June 27, 2024Sex Abuse Litigation
-
June 10-11, 20242024 Probate and Trust Law Section Conference
-
June 11, 2024FBA 2024 Federal Practice Seminar
-
June 2024Robins Kaplan Secures Landmark $7.75 Million Verdict in Aerosol Duster Misuse Case
-
June 2024To Seize or Not to Seize: Campus Protests and Police Uses of Force
-
June 2024Communicating Your Estate Plan: A Helpful Tool, Not a Fix-All
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Tyco Healthcare Group LP v. Mutual Pharm. Co., Inc.
An exceptional case finding is not supported when there was a genuine issue regarding how to test to determine if a claim element is present.
October 25, 2016
Case Name: Tyco Healthcare Group LP v. Mutual Pharm. Co., Inc., Civ. No. 07-cv-1299 (SRC)(CLW), 2016 U.S. Dist. LEXIS 95789 (D.N.J. July 22, 2016) (Chesler, J.)
Drug Product and Patent(s)-in-Suit: Restoril® (temazepam); U.S. Patent No. 5,211,954 (“the ’954 patent”)
Nature of the Case and Issue(s) Presented: The issue before the court was to determine if the case was exceptional and, as such, to determine if attorneys’ fees should be awarded. Mutual argued that the case was exceptional because its ANDA product specifically did not have a claim limitation that the surface area of the product be less than a certain amount. In fact, Mutual’s ANDA product required a surface area significantly larger than the claimed limitation. As Tyco had lost all claim-construction arguments and the Federal Circuit had remanded the case related to one of Mutual’s antitrust causes of action, Mutual asserted that the case was exceptional.
Tyco argued that there was a genuine dispute over how to determine the surface area. While Mutual’s ANDA filing required a larger surface area, the facts showed that Mutual had difficulties obtaining a product with the required surface area, and that these developmental products fell within the claim limitation. In addition, Tyco disputed the temperature at which Mutual was performing the test. The court found that the case was not exceptional.
Why Tyco Prevailed: The district court found the case not to be exceptional because there was a genuine dispute over how to perform the test for surface area. The court found that both sides had presented credible, supported arguments for why their particular temperature was the correct one. The court rejected Mutual’s argument that Tyco’s position was frivolous simply because Tyco ultimately did not prevail. The court further relied on the fact that Mutual had challenges in its development to obtain products that did not infringe the patent as additional evidence as to why the case was not frivolous.
Lastly, the court rejected that the remand on Mutual’s antitrust claim established an exceptional case. The court found that there was no evidence that Tyco had engaged in sham litigation or bad faith. Rather, Tyco’s actions were to protect its monopoly under the patent.
Related Publications
Related News
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.